Table 3. Genotype×treatment interaction results, total events and event rates by genotype and treatment group.
| Number of events, event rates per 1000 person-years | Genotype-specific treatment effect hazard ratio (95%CI) | Genotype-by-treatment interaction P values* | ||||||
| Outcome - Variant | Genotype | AML | LIS | CHL | AML vs. LIS | AML vs. CHL | AML vs. LIS | AML vs. CHL |
| CHD (primary outcome) | ||||||||
| −690 C>T | CC | 642, 19.2 | 618, 18.6 | 1065, 18.8 | 1.03 (0.92–1.15) | 1.02 (0.92–1.12) | ||
| CT+TT | 89, 20.8 | 90, 21.2 | 175, 24.6 | 0.98(0.73–1.32) | 0.85(0.66–1.09) | 0.77 | 0.19 | |
| −922 A>G | AA | 377, 19.6 | 345, 17.8 | 604, 18.8 | 1.10 (0.95–1.27) | 1.04 (0.91–1.18) | ||
| AG+GG | 352, 19.1 | 363, 20.0 | 635, 20.1 | 0.95 (0.82–1.10) | 0.95 (0.83–1.08) | 0.17 | 0.34 | |
| glu298asp G>T | GG | 428, 19.3 | 384, 17.6 | 701, 19.0 | 1.10 (0.96–1.26) | 1.02 (0.90–1.15) | ||
| GT+TT | 303, 19.4 | 323, 20.6 | 537, 20.1 | 0.94 (0.81–1.10) | 0.97 (0.84–1.11) | 0.16 | 0.60 | |
| Stroke | ||||||||
| −690 C>T | CC | 310, 9.1 | 361, 10.7 | 547, 9.5 | 0.85 (0.73–0.99) | 0.96 (0.83–1.10) | ||
| CT+TT | 25, 5.7 | 50, 11.6 | 64, 8.7 | 0.49 (0.31–0.80) | 0.66 (0.42–1.05) | 0.04 | 0.13 | |
| −922 A>G | AA | 172, 8.8 | 221, 11.3 | 327, 10.1 | 0.78 (0.64–0.95) | 0.87 (0.72–1.05) | ||
| AG+GG | 164, 8.8 | 190, 10.3 | 284, 8.8 | 0.85 (0.69–1.05) | 0.99 (0.82–1.20) | 0.56 | 0.33 | |
| glu298asp G>T | GG | 217, 9.7 | 241, 11.0 | 368, 9.9 | 0.88 (0.73–1.06) | 0.98 (0.83–1.16) | ||
| GT+TT | 118, 7.4 | 170, 10.7 | 243, 8.9 | 0.70 (0.55–0.88) | 0.83 (0.67–1.04) | 0.12 | 0.24 | |
| Heart failure | ||||||||
| −690 C>T | CC | 582, 17.4 | 490, 14.8 | 697, 12.2 | 1.18 (1.05–1.33) | 1.43 (1.28–1.59) | ||
| CT+TT | 73, 17.1 | 72, 16.9 | 98, 13.6 | 1.02 (0.74–1.42) | 1.27 (0.94–1.72) | 0.40 | 0.47 | |
| −922 A>G | AA | 317, 16.5 | 270, 13.9 | 383, 11.8 | 1.18 (1.01–1.39) | 1.39 (1.20–1.61) | ||
| AG+GG | 337, 18.4 | 292, 16.2 | 412, 12.9 | 1.14 (0.97–1.33) | 1.42 (1.24–1.65) | 0.75 | 0.80 | |
| glu298asp G>T | GG | 403, 18.3 | 325, 14.9 | 448, 12.0 | 1.22 (1.06–1.42) | 1.52 (1.33–1.74) | ||
| GT+TT | 252, 16.1 | 237, 15.1 | 344, 12.8 | 1.07 (0.90–1.28) | 1.27 (1.08–1.49) | 0.25 | 0.09 | |
| All-cause mortality | ||||||||
| −690 C>T | CC | 977, 27.4 | 1027, 28.8 | 1757, 29.1 | 0.95 (0.87–1.04) | 0.94 (0.87–1.01) | ||
| CT+TT | 135, 29.7 | 148, 32.4 | 215, 28.1 | 0.93 (0.73–1.17) | 1.07 (0.86–1.33) | 0.82 | 0.27 | |
| −922 A>G | AA | 575, 28.0 | 602, 28.9 | 1006, 29.4 | 0.97 (0.86–1.08) | 0.95 (0.86–1.05) | ||
| AG+GG | 534, 27.3 | 572, 29.4 | 963, 28.6 | 0.93 (0.82–1.04) | 0.95 (0.86–1.06) | 0.61 | 0.96 | |
| glu298asp G>T | GG | 687, 29.1 | 670, 28.7 | 1170, 29.7 | 1.01 (0.91–1.13) | 0.98 (0.89–1.08) | ||
| GT+TT | 425, 25.6 | 505, 30.0 | 798, 28.1 | 0.85 (0.75–0.97) | 0.91 (0.81–1.03) | 0.04 | 0.36 | |
| End-stage renal disease | ||||||||
| −690 C>T | CC | 105, 3.0 | 102, 3.0 | 159, 2.7 | 1.02 (0.78–1.34) | 1.11 (0.87–1.42) | ||
| CT+TT | 7, 1.6 | 10, 2.3 | 13, 1.8 | 0.70 (0.27–1.85) | 0.91 (0.36–2.29) | 0.46 | 0.68 | |
| −922 A>G | AA | 63, 3.2 | 59, 3.0 | 92, 2.8 | 1.07 (0.75–1.53) | 1.14 (0.82–1.57) | ||
| AG+GG | 47, 2.5 | 54, 2.9 | 80, 2.5 | 0.85 (0.58–1.26) | 1.01 (0.70–1.44) | 0.40 | 0.63 | |
| glu298asp G>T | GG | 77, 3.4 | 73, 3.3 | 114, 3.0 | 1.04 (0.75–1.43) | 1.12 (0.84–1.50) | ||
| GT+TT | 35, 2.2 | 39, 2.4 | 57, 2.1 | 0.90 (0.57–1.43) | 1.05 (0.69–1.60) | 0.63 | 0.80 | |
*P value: minor allele carriers combined into one group due to low numbers of events in some cells, Ho = interaction coefficient equals zero (1-degree of freedom test). AML, amlodipine; CHD, coronary heart disease (including fatal CHD and nonfatal myocardial infarction), CHL, chlorthalidone; CI, confidence interval; LIS, lisinopril.